136 related articles for article (PubMed ID: 16146729)
1. Molecular mechanisms responsible for the involvement of tissue transglutaminase in human diseases: Celiac Disease.
Amantea G; Cammarano M; Zefferino L; Martin A; Romito G; Piccirillo M; Gentile V
Front Biosci; 2006 Jan; 11():249-55. PubMed ID: 16146729
[TBL] [Abstract][Full Text] [Related]
2. Role of transglutaminase-catalyzed reactions in the post-translational modifications of proteins responsible for immunological disorders.
De Vivo G; Martin A; Trotta T; Gentile V
Inflamm Allergy Drug Targets; 2008 Mar; 7(1):24-9. PubMed ID: 18473897
[TBL] [Abstract][Full Text] [Related]
3. Role of the transglutaminase enzymes in the nervous system and their possible involvement in neurodegenerative diseases.
De Vivo G; Di Lorenzo R; Ricotta M; Gentile V
Curr Med Chem; 2009; 16(36):4767-73. PubMed ID: 19929789
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiological roles of transglutaminase - catalyzed reactions in the pathogenesis of human diseases.
Martin A; De Vivo G; Iannaccone M; Stefanile A; Serretiello E; Gentile V
Inflamm Allergy Drug Targets; 2012 Aug; 11(4):278-84. PubMed ID: 22680626
[TBL] [Abstract][Full Text] [Related]
5. Transglutaminase-catalyzed reactions responsible for the pathogenesis of celiac disease and neurodegenerative diseases: from basic biochemistry to clinic.
Martin A; Romito G; Pepe I; De Vivo G; Merola MR; Limatola A; Gentile V
Curr Med Chem; 2006; 13(16):1895-902. PubMed ID: 16842200
[TBL] [Abstract][Full Text] [Related]
6. Transglutaminase-catalyzed post-translational modifications of proteins in the nervous system and their possible involvement in neurodegenerative diseases.
De Vivo G; Gentile V
CNS Neurol Disord Drug Targets; 2008 Oct; 7(4):370-5. PubMed ID: 18991665
[TBL] [Abstract][Full Text] [Related]
7. Transglutaminases as possible therapeutic targets in neurodegenerative diseases.
Martin A; De Vivo G; Ricotta M; Iannuzzi M; Gentile V
Recent Pat CNS Drug Discov; 2010 Nov; 5(3):195-202. PubMed ID: 20636272
[TBL] [Abstract][Full Text] [Related]
8. Physio-pathological roles of transglutaminase-catalyzed reactions.
Ricotta M; Iannuzzi M; Vivo GD; Gentile V
World J Biol Chem; 2010 May; 1(5):181-7. PubMed ID: 21541002
[TBL] [Abstract][Full Text] [Related]
9. Deamidation and cross-linking of gliadin peptides by transglutaminases and the relation to celiac disease.
Skovbjerg H; Koch C; Anthonsen D; Sjöström H
Biochim Biophys Acta; 2004 Nov; 1690(3):220-30. PubMed ID: 15511629
[TBL] [Abstract][Full Text] [Related]
10. The function of tissue transglutaminase in celiac disease.
Di Sabatino A; Vanoli A; Giuffrida P; Luinetti O; Solcia E; Corazza GR
Autoimmun Rev; 2012 Aug; 11(10):746-53. PubMed ID: 22326684
[TBL] [Abstract][Full Text] [Related]
11. Transglutaminase 2-targeted autoantibodies in celiac disease: Pathogenetic players in addition to diagnostic tools?
Lindfors K; Mäki M; Kaukinen K
Autoimmun Rev; 2010 Sep; 9(11):744-9. PubMed ID: 20547248
[TBL] [Abstract][Full Text] [Related]
12. Transglutaminase inhibition as a possible therapeutical approach to protect cells from death in neurodegenerative diseases.
Iannaccone M; Serretiello E; De Vivo G; Martin A; Stefanile A; Titta F; Gentile V
Recent Pat CNS Drug Discov; 2013 Aug; 8(2):161-8. PubMed ID: 23688272
[TBL] [Abstract][Full Text] [Related]
13. Blocking peptides decrease tissue transglutaminase processing of gliadin in vitro.
Hoffmann K; Alminger M; Andlid T; Chen T; Olsson O; Sandberg AS
J Agric Food Chem; 2009 Nov; 57(21):10150-5. PubMed ID: 19813732
[TBL] [Abstract][Full Text] [Related]
14. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase.
Arentz-Hansen H; Körner R; Molberg O; Quarsten H; Vader W; Kooy YM; Lundin KE; Koning F; Roepstorff P; Sollid LM; McAdam SN
J Exp Med; 2000 Feb; 191(4):603-12. PubMed ID: 10684852
[TBL] [Abstract][Full Text] [Related]
15. Celiac anti-type 2 transglutaminase antibodies induce differential effects in fibroblasts from celiac disease patients and from healthy subjects.
Paolella G; Lepretti M; Barone MV; Nanayakkara M; Di Zenzo M; Sblattero D; Auricchio S; Esposito C; Caputo I
Amino Acids; 2017 Mar; 49(3):541-550. PubMed ID: 27613408
[TBL] [Abstract][Full Text] [Related]
16. The industrial food additive, microbial transglutaminase, mimics tissue transglutaminase and is immunogenic in celiac disease patients.
Matthias T; Jeremias P; Neidhöfer S; Lerner A
Autoimmun Rev; 2016 Dec; 15(12):1111-1119. PubMed ID: 27640315
[TBL] [Abstract][Full Text] [Related]
17. Possible physiopathological effects of the transglutaminase activity on the molecular mechanisms responsible for human neurodegenerative diseases.
Iannaccone M; Titta F; Serretiello E; Monfregola M; Gentile V
Recent Pat CNS Drug Discov; 2014; 9(2):76-84. PubMed ID: 25386917
[TBL] [Abstract][Full Text] [Related]
18. Tissue transglutaminase: an enzyme with a split personality.
Chen JS; Mehta K
Int J Biochem Cell Biol; 1999 Aug; 31(8):817-36. PubMed ID: 10481269
[TBL] [Abstract][Full Text] [Related]
19. Tissue transglutaminase-mediated formation and cleavage of histamine-gliadin complexes: biological effects and implications for celiac disease.
Qiao SW; Piper J; Haraldsen G; Oynebråten I; Fleckenstein B; Molberg O; Khosla C; Sollid LM
J Immunol; 2005 Feb; 174(3):1657-63. PubMed ID: 15661929
[TBL] [Abstract][Full Text] [Related]
20. Transglutaminases - possible drug targets in human diseases.
Gentile V; Cooper AJ
Curr Drug Targets CNS Neurol Disord; 2004 Apr; 3(2):99-104. PubMed ID: 15078184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
